8-K: Aspire Biopharma Secures $100M Equity Line of Credit

Aspire Biopharma Holdings, Inc. entered into a new Equity Line of Credit agreement for up to $100 million, replacing a prior facility, to fund general corporate purposes.

Summary

• Aspire Biopharma Holdings, Inc. (ASBP) entered into a new Purchase Agreement (Equity Line of Credit ELOC Agreement) with Arena Business Solutions Global SPC II, Ltd. on November 11, 2025.
• The ELOC Agreement grants the Company the right, but not the obligation, to direct Arena to purchase up to $100,000,000 in shares of its common stock.
• The purchase price for shares under the ELOC will be 96% of the Volume Weighted Average Price (VWAP) of the Company's common stock during the trading day commencing on the Advance Notice date, subject to adjustment.
• The term of the ELOC Agreement is 36 months from the execution date or until the maximum amount of ELOC Shares is purchased, or earlier termination.
• In consideration for the ELOC, the Company agreed to issue Transaction Fee Shares and pay Arena's due diligence and legal fees totaling $40,000, with $20,000 paid in cash and the remaining $20,000 paid by issuing 162,338 shares of common stock.
• The Company will also issue Commitment Fee Shares with an aggregate dollar value of $250,000, calculated based on the lowest 1-Trading Day VWAP of the common shares from the five trading days preceding the initial registration statement's effectiveness, subject to a true-up provision.
• The Company and Arena mutually terminated a previous ELOC Agreement, which was originally entered into on February 13, 2025, effective immediately.
• The Company is limited to delivering up to two Advance Notices per trading day, with maximum advance amounts ranging from $5 million to $20 million depending on the time of notice and daily trading value.
• The aggregate number of common shares issued under the ELOC cannot exceed 19.99% of the outstanding common shares as of the agreement date (Exchange Cap) unless shareholder approval is obtained.
• The Investor's beneficial ownership is limited to 9.99% of the then outstanding common shares (Ownership Limitation).
• The Investor is prohibited from selling more than 15% of the Daily Value Traded on any trading day without the Company's written consent, unless the Company is in material default.
• The Company is prohibited from entering into certain 'Variable Rate Transactions' for a specified period (earlier of $50M purchased, 12 months after initial registration effectiveness, or 3 months after termination), with a $250,000 cash penalty for breach, subject to certain exemptions.
• As of November 10, 2025, the Company had 79,896,761 common shares issued and outstanding out of 490,000,000 authorized, and no preferred shares outstanding out of 5,000,000 authorized.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While securing a significant capital facility is beneficial for a biopharma company, the potential for dilution and the associated fees introduce some negative aspects. The replacement of a prior ELOC suggests a continuation of a known financing strategy, making it a somewhat expected operational event.

Positives

• Secured access to up to $100 million in capital, providing significant funding flexibility for working capital and general corporate purposes.
• The Company retains the sole discretion to request advances, meaning it is not obligated to draw funds if market conditions are unfavorable or capital is not needed.
• The termination of the prior ELOC agreement and establishment of a new one with the same investor suggests a continued relationship and potentially refined terms.

Negatives

• The issuance of shares at 96% of VWAP means existing shareholders will experience dilution at a discount to the market price.
• The payment of $40,000 in fees (partially in cash and partially in shares) and the issuance of $250,000 in Commitment Fee Shares represent costs associated with securing the financing.
• The Exchange Cap (19.99% of outstanding shares) and Ownership Limitation (9.99% for the investor) may restrict the Company's ability to access the full $100 million without obtaining shareholder approval, which could be a lengthy process.
• Restrictions on the Company's ability to enter into other 'Variable Rate Transactions' for a period could limit future financing options or incur penalties if breached.

Risks

• Significant dilution for existing shareholders due to the issuance of new common stock at a discount to the market price.
• The Company's ability to draw funds is contingent on an effective registration statement, and market conditions (e.g., trading halts, Material Outside Events) could suspend the right to make advances.
• Failure to obtain shareholder approval for issuances exceeding the 19.99% Exchange Cap could limit the total capital accessible under the ELOC.
• The Company has previously received deficiency notices relating to Nasdaq delisting, which, while disclosed, remain a potential concern for its listing status.
• The purchase price being tied to VWAP means the Company will receive less per share if its stock price declines during the pricing period.

Future Outlook

The Company has secured a flexible financing mechanism to potentially raise up to $100 million over the next three years, which it intends to use for working capital and general corporate purposes. This facility provides a potential source of capital to support future operations and growth, contingent on market conditions and the Company's discretion to draw funds. The Company is committed to filing a registration statement to enable the resale of shares by the investor.

Industry Context

Equity Line of Credit facilities are a common financing tool for smaller and growth-stage biopharma companies, which often require substantial capital for research, development, and operational expenses. This type of financing provides access to capital on an 'as-needed' basis, offering flexibility but also carrying the risk of dilution for existing shareholders, a trade-off frequently observed in the capital-intensive biotechnology sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the terms of this ELOC against global benchmarks.

Stakeholder Impact

• Shareholders: Will experience potential dilution from the issuance of new shares at a discount, but the Company gains access to capital for operations and growth, which could support long-term value.
• Company: Gains a flexible source of capital for working capital and general corporate purposes, enhancing liquidity and operational stability.
• Creditors: Improved financial flexibility from the ELOC could indirectly enhance the Company's ability to meet its obligations.

Next Steps

• The Company must file a registration statement with the SEC for the resale of ELOC Shares and ELOC Commitment Shares no later than ten business days following November 11, 2025.
• The Company may, at its discretion, deliver Advance Notices to Arena to request purchases of common stock under the ELOC Agreement.
• The Company will need to obtain shareholder approval if it intends to issue common shares exceeding 19.99% of its outstanding shares under the ELOC.

Key Dates

Keywords

Equity Line of Credit, ELOC, Capital Raise, Dilution, Common Stock, SEC Filing, Biopharma, Financing, Aspire Biopharma, ASBP, Arena Business Solutions